Each year, flu experts from around the world gather to map out recommendations for next winter's flu vaccine. This year, it's ...

NEW YORK - OS Therapies, Inc. (NYSE-A: OSTX), a small-cap biotech firm with a market capitalization of $42 million focusing on cancer treatment solutions, has announced the completion of its Phase 2b ...

Reports of impending layoffs, a buyout offer, and a return-to-office mandate have put a damper on FDA staff morale ...

Shares of Travere Therapeutics (NASDAQ:TVTX) surged 14% Tuesday following the company's announcement of a successful Type C ...

The Trump administration's "short pause" on communications, expected to end on Feb. 1, has affected FDA updates on food ...

The Trump administration’s freeze on communications from U.S. health agencies is leading to another disruption: the abrupt cancellation of scientific meetings. The move covers a swath of health ...

Earlier this month, the U.S. Food and Drug Administration (FDA) announced a public meeting entitled “Interested Parties Meeting: Implementation of the Best Pharmaceuticals for Children Act and ...

In honor of Rare Disease Day on February 28, 2025, we will publish a series of posts throughout the month on As Prescribed ...

The FDA, which first considered this policy under ... tobacco products or to population health than other products meeting the definition of a cigarette." Mitch Zeller, who directed the FDA's ...

The Health and Human Services Office of Inspector General has found that, in a few cases, FDA officials veered from the accelerated approval pathway.

Awakn announced a positive outcome from a Pre-Investigational New Drug ("Pre-IND") meeting with the U.S. Food and Drug Administration ("FDA") regarding AWKN-002, a proprietary oral thin film ("OTF ...

Amid the uproar over the firing of 18 inspectors general, a report offering a coda to the aducanumab approval episode has ...